| Cullinan Management Inc (CGEM) | |||
|---|---|---|---|
| 16.67 1.04 (6.65%) | 04-23 16:00 | ||
| Open: | 15.44 | Pre. Close: | 15.63 |
| High: | 16.87 | Low: | 15.44 |
| Volume: | 954,048 | Market Cap: | 718(M) |
| Stock Technical Analysis | |
|---|---|
| Overall: |  |
| Target: | Six months: 21.57 One year: 24.08 |
| Support: | Support1: 14.98 Support2: 12.46 |
| Resistance: | Resistance1: 18.47 Resistance2: 20.62 |
| Pivot: | 16.92  |
| Moving Averages: | MA(5): 16.78 MA(20): 17.00 MA(100): 14.25  MA(250): 11.75 |
| MACD: | MACD(12,26): -0.06 Signal(12,26,9): 0.05 |
| %K %D: | %K(14,3): 14.51 %D(3): 21.91 |
| RSI: | RSI(14): 48.87 |
| 52-Week: | High: 20.62 Low: 7.64 Change(%): 59.8 |
| Average Vol(K): | 3-Month: 546 10-Days: 925 |
| Prices Prediction (Update @5:00pm) | ||
|---|---|---|
| If tomorrow: | Open lower | Open higher |
| High: | 16.878 - 16.962 | 16.962 - 17.046 |
| Low: | 15.257 - 15.338 | 15.338 - 15.419 |
| Close: | 16.532 - 16.668 | 16.668 - 16.806 |
| Price, MAs and Bollinger Bands |
|---|
| Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and NEUTRAL in mid-long term.[ CGEM ] has closed above bottom band by 40.3%. Bollinger Bands are 19.1% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices. |
| Company profile |
|---|
| Cullinan Oncology Inc., a biopharmaceutical company, focuses on developing a pipeline of targeted oncology and immuno-oncology therapies for cancer patients in the United States. The company's lead candidate is the CLN-081, an orally available small molecule that is in a Phase I/IIa dose escalation and expansion trial for treating patients with non-small cell lung cancer. Its preclinical products include CLN-049, a humanized bispecific antibody for the treatment of acute myeloid leukemia; CLN-619, a monoclonal antibody for the treatment of solid tumors; CLN-617, a fusion protein for the treatment of solid tumors; CLN-978, a T cell engaging antibody for B-cell malignancies; Opal, a bispecific fusion protein to block the PD-1 axis, and to activate the 4-IBB/CD137 pathway on T cells in tumors; and Jade, a cell therapy to target a novel senescence and cancer-related protein. The company has collaboration agreements with Cullinan Pearl Corp. to develop, manufacture, and commercialize CLN-081 and products containing CLN-081; and Adimab, LLC to discover and/or optimize antibodies. Cullinan Oncology, Inc. was incorporated in 2016 and is headquartered in Cambridge, Massachusetts. |
| Stock chart |
|---|
 |
| Financial Analysis | |
|---|---|
| Price to Book Value: | Underperform |
| P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. | |
| Price to Earnings: | Underperform |
| PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). | |
| Discounted cash flow: | Neutral |
| DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. | |
| Return on Assets: | Underperform |
| ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. | |
| Return on Equity: | Underperform |
| ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. | |
| Debt to Equity: | Neutral |
| evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. | |
| Stock Basics & Statistics | |
|---|---|
| Exchange: NASDAQ Global Select | |
| Sector: Healthcare | |
| Industry: Biotechnology | |
| Shares Out. (M) | 43.07 |
| Shares Float (M) | 25.88 |
| % Held by Insiders | 6.40 |
| % Held by Institutions | 95.29 |
| Shares Short (K) | 1440 |
| Shares Short Prior Month (K) | 694 |
| Stock Financials | |
|---|---|
| EPS | -3.690 |
| Book Value (p.s.) | 10.580 |
| Profit Margin | |
| Operating Margin | |
| Return on Assets (ttm) | -22.8 |
| Return on Equity (ttm) | -31.4 |
| Qtrly Rev. Growth | |
| Gross Profit (p.s.) | |
| Sales Per Share | |
| EBITDA (p.s.) | -4.419 |
| Qtrly Earnings Growth | |
| Operating Cash Flow (M) | -134.28 |
| Levered Free Cash Flow (M) | -88.76 |
| Stock Valuation | |
|---|---|
| PE Ratio | -4.52 |
| PEG Ratio | |
| Price to Book value | 1.58 |
| Price to Sales | |
| Price to Cash Flow | -5.35 |
| Stock Dividends | |
|---|---|
| Dividend | |
| Dividend Yield | |
| Dividend Growth | |
